Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Kremyanskaya · SciRah

Researcher profile · Semantic Scholar

M. Kremyanskaya

Share profile

M. Kremyanskaya — researcher profile on SciRah

h-index: 27
Works: 175
Citations: 2,480

Most-cited papers

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia
J. Mascarenhas, H. Kosiorek, J. Prchal, A. Rambaldi +39 more
2022Blood129 citations Open access
Semantic Scholar
Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial.
Eunice S. Wang, G. Issa, Harry P. Erba, Jessica K. Altman +32 more
2024The Lancet Oncology107 citations
Semantic Scholar
MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis
J. Mascarenhas, M. Kremyanskaya, A. Patriarca, F. Palandri +20 more
2023Journal of Clinical Oncology72 citations Open access
Semantic Scholar
Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia
H. Erba, A. Fathi, G. Issa, J. Altman +15 more
2022Blood67 citations Open access
Semantic Scholar
Diagnosis and Treatment of Polycythemia Vera: A Review
D. Tremblay, M. Kremyanskaya, John Mascarenhas, Ronald Hoffman
2024Journal of the American Medical Association (JAMA)50 citations Open access
Semantic Scholar
Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera.
M. Kremyanskaya, Andrew T. Kuykendall, N. Pemmaraju, Ellen Ritchie +15 more
2024New England Journal of Medicine47 citations
Semantic Scholar
Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies
J. Feld, D. Tremblay, Mikaela Dougherty, Tina Czaplinska +12 more
2021HemaSphere44 citations Open access
Semantic Scholar
Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis
A. Gerds, C. Harrison, J. Kiladjian, Ruben A. Mesa +15 more
2024Blood Advances42 citations Open access
Semantic Scholar
Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis.
C. Harrison, V MNSSVKR GUPTA, A. Gerds, R. Rampal +21 more
2022Future Oncology40 citations Open access
Semantic Scholar
A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis
J. Mascarenhas, A. Migliaccio, H. Kosiorek, R. Bhave +30 more
2023Clinical Cancer Research25 citations Open access
Semantic Scholar
Hepcidin Mimetics in Polycythemia Vera: Resolving the Irony of Iron deficiency and Erythrocytosis
S. Handa, Yelena Z. Ginzburg, R. Hoffman, M. Kremyanskaya
2022Current opinion in hematology21 citations
Semantic Scholar
MPN-375 BET Inhibitor Pelabresib (CPI-0610) Combined With Ruxolitinib in Patients With Myelofibrosis - JAK Inhibitor-Naïe or With Suboptimal Response to Ruxolitinib - Preliminary Data From the MANIFEST Study.
J. Mascarenhas, M. Kremyanskaya, A. Patriarca, C. Harrison +18 more
2022Clinical Lymphoma, Myeloma & Leukemia18 citations
Semantic Scholar
Contemporary Challenges in Polycythemia Vera Management From the Perspective of Patients and Physicians.
Andrew T. Kuykendall, J. Fine, M. Kremyanskaya
2024Clinical Lymphoma, Myeloma & Leukemia17 citations Open access
Semantic Scholar
Immunoglobulin repletion during blinatumomab therapy does not reduce the rate of secondary hypogammaglobulinemia and associated infectious risk
S. Wo, Hannah Levavi, J. Mascarenhas, M. Kremyanskaya +3 more
2022Blood Research15 citations Open access
Semantic Scholar
Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results
Abdulraheem Yacoub, U. Borate, R. Rampal, H. Ali +17 more
2024Blood Advances14 citations Open access
Semantic Scholar
Treatment of Myelofibrosis Patients with the TGF-β 1/3 Inhibitor AVID200 (MPN-RC 118) Induces a Profound Effect on Platelet Production
J. Mascarenhas, H. Kosiorek, R. Bhave, J. Palmer +27 more
2021Blood13 citations
Semantic Scholar
P504: UPDATED DATA FOR ZIFTOMENIB IN PATIENTS WITH NPM1-MUTATED RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA
A. Fathi, Eunice S. Wang, G. Issa, J. Altman +21 more
2023HemaSphere12 citations Open access
Semantic Scholar
Pelabresib (CPI-0610) As Add-on to Ruxolitinib in Myelofibrosis: Durability of Response and Safety Beyond Week 24 in the Phase 2 MANIFEST Study
C. Harrison, M. Kremyanskaya, P. Bose, V MNSSVKR GUPTA +12 more
2022Blood12 citations
Semantic Scholar
Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis
V MNSSVKR GUPTA, J. Mascarenhas, M. Kremyanskaya, R. Rampal +7 more
2023Blood Advances11 citations Open access
Semantic Scholar
Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis: Results from the ACE-536-MF-001 study.
A. Gerds, C. Harrison, J. Kiladjian, R. Mesa +15 more
2023Journal of Clinical Oncology11 citations Open access
Semantic Scholar
Patient-Specific Pharmacokinetics and Dasatinib Nephrotoxicity
B. Adegbite, Matthew H. Abramson, V. Gutgarts, F. M. Musteata +14 more
2023American Society of Nephrology. Clinical Journal11 citations Open access
Semantic Scholar
Molecularly Targeted Combination Therapy for Advanced Phase Myeloproliferative Neoplasm: MPN-RC 119
M. Bar-Natan, J. Mascarenhas, A. Gerds, R. Mesa +11 more
2022Blood10 citations
Semantic Scholar
Efficacy and Safety of Add-on Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Patients With Suboptimal Response to Ruxolitinib: Final Results From a Phase 2 Study
A. Yacoub, U. Borate, R. Rampal, H. Ali +13 more
2022Blood10 citations Open access
Semantic Scholar
Initial Results from a Phase 1/2 Study Evaluating Divesiran, a Novel Galnac Conjugated siRNA, in Patients with Polycythemia Vera (SANRECO)
M. Kremyanskaya, Ronald Hoffman, Lee Ping Chew, Azizan Sharif +14 more
2024Blood9 citations
Semantic Scholar
Venetoclax in combination with hypomethylating agents in chronic myelomonocytic leukemia: a propensity score matched multicenter cohort study
D. Tremblay, Clifford M. Csizmar, C. Dinardo, S. Ball +21 more
2024Leukemia8 citations
Semantic Scholar
AML-475 Activity, Tolerability, and Resistance Profile of the Menin Inhibitor Ziftomenib in Adults With Relapsed/Refractory NPM1-Mutated AML
H. Erba, Eunice S. Wang, G. Issa, J. Altman +27 more
2023Clinical Lymphoma, Myeloma & Leukemia8 citations
Semantic Scholar
AML-732: Ziftomenib Combined With Intensive Induction Chemotherapy (7+3) in Newly Diagnosed NPM1-m or KMT2A-r Acute Myeloid Leukemia (AML): Updated Phase 1a/b Results From KOMET-007
Harry P. Erba, Eunice S. Wang, Amir T. Fathi, Gail J. Roboz +28 more
2025Clinical Lymphoma, Myeloma & Leukemia7 citations
Semantic Scholar
Modulators of the Hepcidin Pathway in Polycythemia Vera and Myelofibrosis.
M. Kremyanskaya, Y. Ginzburg, Ronald Hoffman
2025Blood7 citations Open access
Semantic Scholar
Rusfertide or placebo plus current standard-of-care therapy for polycythemia vera: Durability of response and safety results through week 52 from the randomized controlled phase 3 VERIFY study
Andrew T. Kuykendall, Aniket Bankar, Kristen M. Pettit, J. Shatzel +23 more
2025Blood6 citations
Semantic Scholar
Results from VERIFY, a phase 3, double-blind, placebo (PBO)-controlled study of rusfertide for treatment of polycythemia vera (PV).
Andrew T. Kuykendall, N. Pemmaraju, Kristen M. Pettit, J. Shatzel +14 more
2025Journal of Clinical Oncology6 citations
Semantic Scholar
Venetoclax (VEN) Improves Response Rates but Not Survival in Patients with Chronic Myelomonocytic Leukemia (CMML) Treated with Hypomethylating Agents (HMA): A Multicenter, Propensity Score Analysis
D. Tremblay, Clifford Csizmar, C. Dinardo, S. Ball +20 more
2023Blood6 citations
Semantic Scholar
Multi-institutional analysis of outcomes in acute myeloid leukemia patients with central nervous system involvement
D. Sastow, Joshua Tatarian, Yosef Riazat-Kesh, K. Farina +8 more
2023Leukemia and Lymphoma6 citations
Semantic Scholar
MPN-469 Rusfertide (PTG-300) Treatment Interruption Reverses Hematological Gains and Upon Reinitiation, Restoration of Clinical Benefit Observed in Patients With Polycythemia Vera.
N. Pemmaraju, A. Kuykendall, M. Kremyanskaya, Yelena Z. Ginzburg +10 more
2022Clinical Lymphoma, Myeloma & Leukemia6 citations
Semantic Scholar
MPN-127: Add-On Parsaclisib (a PI3K5 Inhibitor) in Patients with Myelofibrosis and Suboptimal Response to Ruxolitinib: Interim Analysis from a Phase 2 Study
A. Yacoub, U. Borate, R. Rampal, H. Ali +14 more
20216 citations
Semantic Scholar
Durability of Hematocrit Control in Polycythemia Vera with the First-in-Class Hepcidin Mimetic Rusfertide: Two-Year Follow up Results from the Revive Study
Ellen K. Ritchie, Kristen Pettit, A. Kuykendall, M. Kremyanskaya +4 more
2023Blood5 citations Open access
Semantic Scholar
Pelabresib (CPI-0610) Combined with Ruxolitinib for JAK Inhibitor Treatment-Naïve Patients with Myelofibrosis: Durability of Response and Safety Beyond Week 24
J. Mascarenhas, M. Kremyanskaya, A. Patriarca, V MNSSVKR GUPTA +13 more
2022Blood5 citations Open access
Semantic Scholar
Final Results from the Phase 2 Revive Study Investigating the Hepcidin Mimetic Rusfertide in Patients with Polycythemia Vera (PV)
A. Gerds, A. Kuykendall, M. Kremyanskaya, Ellen K. Ritchie +11 more
2024Blood4 citations
Semantic Scholar
Characterization of disease-propagating stem cells responsible for myeloproliferative neoplasm–blast phase
Xiaoli Wang, R. Rampal, C. Hu, J. Tripodi +13 more
2022JCI Insight4 citations Open access
Semantic Scholar
Phase 1/2 Study Investigating CC-90011, a Potent, Selective, and Reversible Oral Inhibitor of Lysine-Specific Demethylase 1 (LSD1), Plus Concurrent Venetoclax (VEN) and Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML)
C. Dinardo, G. Borthakur, B. Ball, H. Erba +10 more
2021Blood4 citations Open access
Semantic Scholar
Long-term rusfertide treatment in polycythemia vera: Initial results from the phase 2 THRIVE extension study
N. Pemmaraju, Andrew T. Kuykendall, Ellen K. Ritchie, J. Gotlib +10 more
2025Blood3 citations
Semantic Scholar
Evaluating the role of Day 14 bone marrow biopsy and European LeukemiaNet risk classification in predicting overall and relapse‐free survival in acute myeloid leukemia
Metodi Balev, V. Zibara, G. van Hyfte, J. Feld +9 more
2024American journal of hematology/oncology3 citations
Semantic Scholar
The evolving landscape of polycythemia vera therapies
Juana Martinez, Shivani Handa, Alexander Skorodinsky, M. Kremyanskaya
2024Expert Opinion on Pharmacotherapy3 citations
Semantic Scholar
Oral Decitabine/Cedazuridine Is an Effective Ambulatory Therapy for Patients With Myelofibrosis Refractory to JAK2 Inhibitor Therapy.
Shivani Handa, Ganesh Sivakumar, Andrew Srisuwananukorn, A. Dueck +5 more
2024Clinical Lymphoma, Myeloma & Leukemia3 citations Open access
Semantic Scholar
TP53 Alterations Confer Increased Risk of Leukemic Transformation and Worse Survival As Compared to High Molecular Risk Mutations in Patients with Myeloproliferative Neoplasms
Shivani Handa, Yosef Joseph Rene Amel Riazat-Kesh, Richard J. Butterfield, Ganesh Sivakumar +16 more
2024Blood3 citations Open access
Semantic Scholar
P1018: UPDATED RESULTS FROM MANIFEST ARM 2: EFFICACY AND SAFETY OF PELABRESIB (CPI-0610) AS ADD-ON TO RUXOLITINIB IN MYELOFIBROSIS
M. Kremyanskaya, C. Harrison, P. Bose, V MNSSVKR GUPTA +12 more
2023HemaSphere3 citations Open access
Semantic Scholar
MPN-075 Efficacy and Safety of Add-on Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Patients With Low Versus Higher Baseline Platelet Counts: A Subgroup Analysis of Data From a Phase 2 Study.
A. Yacoub, U. Borate, R. Rampal, H. Ali +13 more
2022Clinical Lymphoma, Myeloma & Leukemia3 citations
Semantic Scholar
Recent advances in JAK2 inhibition for the treatment of myelofibrosis
N. Rippel, M. Kremyanskaya
2024Expert Opinion on Pharmacotherapy2 citations
Semantic Scholar
P1016: RUSFERTIDE (PTG-300) IMPROVES POLYCYTHEMIA VERA (PV) RELATED SYMPTOMS IN PV PATIENTS
A. Kuykendall, M. Kremyanskaya, Yelena Z. Ginzburg, N. Pemmaraju +6 more
2023HemaSphere2 citations Open access
Semantic Scholar
S167: EFFICACY AND SAFETY OF LUSPATERCEPT FOR THE TREATMENT OF ANEMIA IN PATIENTS WITH MYELOFIBROSIS: RESULTS FROM THE ACE-536-MF-001 STUDY
A. Gerds, C. Harrison, J. Kiladjian, R. Mesa +15 more
2023HemaSphere2 citations Open access
Semantic Scholar
Dasatinib nephrotoxicity correlates with patient-specific pharmacokinetics
B. Adegbite, M. Abramson, V. Gutgarts, M. Musteață +14 more
2023medRxiv2 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

J. Mascarenhas×18
Invite
J. Mascarenhas — researcher profile on SciRah
R. Rampal×17
Invite
R. Rampal — researcher profile on SciRah
A. Vannucchi×12
Invite
A. Vannucchi — researcher profile on SciRah
S. Verstovsek×12
Invite
S. Verstovsek — researcher profile on SciRah

×11

Invite

J. Kiladjian — researcher profile on SciRah

Invite

A. Gerds — researcher profile on SciRah

A. Kuykendall×10

Invite

A. Kuykendall — researcher profile on SciRah

Invite

M. Talpaz — researcher profile on SciRah

V MNSSVKR GUPTA×8

Invite

V MNSSVKR GUPTA — researcher profile on SciRah

N. Pemmaraju×8

Invite

N. Pemmaraju — researcher profile on SciRah

Invite

A. Yacoub — researcher profile on SciRah

Invite

R. Hoffman — researcher profile on SciRah